TY - JOUR
T1 - The alpha-synuclein mutation E46K promotes aggregation in cultured cells
AU - Pandey, Neeraj
AU - Schmidt, Robert E.
AU - Galvin, James E.
N1 - Funding Information:
We would like to thank Dr. Michele Goedert for AS construct. We are grateful to Dr. John Trojanowski for AS antibodies. This work was supported by grants from the American Federation on Aging Research and the National Institute on Aging (K08 AG20764). Dr. Galvin is a recipient of the Paul Beeson Physician Faculty Scholar Award in Aging Research. This project was also supported by generous gifts from the Alan A. and Edith L. Wolff Charitable Trust and the Blue Gator Foundation.
PY - 2006/2
Y1 - 2006/2
N2 - Parkinson's disease (PD) is characterized by the polymerization of wild-type (WT) or mutant alpha-synuclein (AS) into aggregates and fibrils, which are observed as Lewy bodies (LBs) and Lewy neurites (LNs) in PD patients. However, inability to demonstrate aggregation in many cell culture systems is a major drawback for effective in vitro modeling of AS aggregation. Utilizing PCR-based cloning approach, we generated A30P, A53T, and the recently reported E46K encoding mutation in the KTKEGV repeat region of AS gene. While cloning E46K mutant, a glycine deletion mutation (E46KΔG) adjacent to the intended lysine mutation was serendipitously generated. Expression of mutant constructs and green fluorescent protein (GFP)-tagged mutant constructs in catecholaminergic SH-SY5Y (5Y) cells revealed 40% of AS-E46KΔG and 18% of AS-E46K transfected cells formed aggregates as compared to 12% in AS-A53T, 6% in AS-WT, and 2% in AS-A30P transfected cells. Western blot analysis demonstrated the formation of high molecular weight AS aggregates. Electron microscopic analysis of 5Y cells expressing the E46K and E46KΔG mutants demonstrated two distinct kinds of inclusions: Type I, which showed dense granular profile; and Type II, which were largely membranous vacuolar inclusions without granular material. These two inclusions are reminiscent of Lewy bodies and pale bodies observed in PD postmortem brain samples. Our results demonstrate that mutations in 4th KTKEGV repeat lead to higher propensity of aggregation of AS compared to other mutants.
AB - Parkinson's disease (PD) is characterized by the polymerization of wild-type (WT) or mutant alpha-synuclein (AS) into aggregates and fibrils, which are observed as Lewy bodies (LBs) and Lewy neurites (LNs) in PD patients. However, inability to demonstrate aggregation in many cell culture systems is a major drawback for effective in vitro modeling of AS aggregation. Utilizing PCR-based cloning approach, we generated A30P, A53T, and the recently reported E46K encoding mutation in the KTKEGV repeat region of AS gene. While cloning E46K mutant, a glycine deletion mutation (E46KΔG) adjacent to the intended lysine mutation was serendipitously generated. Expression of mutant constructs and green fluorescent protein (GFP)-tagged mutant constructs in catecholaminergic SH-SY5Y (5Y) cells revealed 40% of AS-E46KΔG and 18% of AS-E46K transfected cells formed aggregates as compared to 12% in AS-A53T, 6% in AS-WT, and 2% in AS-A30P transfected cells. Western blot analysis demonstrated the formation of high molecular weight AS aggregates. Electron microscopic analysis of 5Y cells expressing the E46K and E46KΔG mutants demonstrated two distinct kinds of inclusions: Type I, which showed dense granular profile; and Type II, which were largely membranous vacuolar inclusions without granular material. These two inclusions are reminiscent of Lewy bodies and pale bodies observed in PD postmortem brain samples. Our results demonstrate that mutations in 4th KTKEGV repeat lead to higher propensity of aggregation of AS compared to other mutants.
KW - Aggregation
KW - Alpha-synuclein
KW - Lewy bodies
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=30444457574&partnerID=8YFLogxK
U2 - 10.1016/j.expneurol.2005.10.019
DO - 10.1016/j.expneurol.2005.10.019
M3 - Article
C2 - 16325180
AN - SCOPUS:30444457574
SN - 0014-4886
VL - 197
SP - 515
EP - 520
JO - Experimental Neurology
JF - Experimental Neurology
IS - 2
ER -